Lv4
515 积分 2020-08-03 加入
Best Practices for the Multidisciplinary Care of Patients With Early-Stage Driver-Mutated Non-Small Cell Lung Cancer
6天前
已完结
Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial
22天前
已完结
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial
27天前
已完结
Upfront management of brain metastases in oncogene‑addicted NSCLC – An EORTC survey
1个月前
已完结
ERBB2-Activating Mutations and Co-Occurring Genomic Alterations Contribute to Disease Heterogeneity in Patients With ERBB2-Mutant Lung Cancer
1个月前
已完结
Novel antibody-drug conjugates based on DXd-ADC technology
1个月前
已完结
Survival and prognostic factors of HER2-mutant advanced non-small cell lung cancer with brain metastases
1个月前
已完结
Survival and prognostic factors of HER2-mutant advanced non-small cell lung cancer with brain metastases
1个月前
已完结
Trastuzumab Deruxtecan for ERBB2-Mutant Metastatic Non-Small Cell Lung Cancer With or Without Brain Metastases: A Secondary Analysis of Randomized Clinical Trials
1个月前
已完结
Interstitial lung disease in patients treated with antibody-drug conjugates: a review
1个月前
已完结
皖公网安备34019202002308
